Cheng Yi Pharmaceutical completes board election, with Yan Yiyi appointed as chairman

On May 20th, Cheng Yi Pharmaceutical (603811) announced that the company had recently held its 2024 annual general meeting of shareholders, which approved the relevant proposals for the election of the fifth board of directors and completed the election of the board of directors and the appointment of senior management personnel. The term of office of the new board of directors is three years from the date of approval by the 2024 annual general meeting of shareholders, with Yan Yiyi serving as the chairman.

The newly appointed members of the company's board of directors include non independent directors Zhao Chunjian, Zhang Zhihong, Ke Zehui, and Zhang Gaoqiao, employee director Zeng Huanqun, and independent directors Li Wen, Huang Ming, and Zhou Chunping. Each specialized committee has also conducted corresponding elections to ensure that independent directors hold a majority in the audit, nomination, and compensation and assessment committees. In addition, the company has also appointed several senior management personnel, including General Manager Zhao Chunjian and Deputy General Manager, with terms consistent with the board of directors. Zhang Yan was hired as the securities affairs representative to assist the secretary of the board of directors.

In the first quarter of 2025, Cheng Yi Pharmaceutical achieved a revenue of 186 million yuan and a net profit attributable to the parent company of 45.79 million yuan.

Reprinted from: Tencent Micro Securities Mini Program - Caizhongshe